133 related articles for article (PubMed ID: 32192445)
1. Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach.
Duhazé J; Caubet M; Hässler S; Bachelet D; Allez M; Deisenhammer F; Fogdell-Hahn A; Gleizes A; Hacein-Bey-Abina S; Mariette X; Pallardy M; Broët P;
BMC Med Res Methodol; 2020 Mar; 20(1):69. PubMed ID: 32192445
[TBL] [Abstract][Full Text] [Related]
2. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.
Yogurtcu ON; Sauna ZE; McGill JR; Tegenge MA; Yang H
AAPS J; 2019 Aug; 21(5):96. PubMed ID: 31376048
[TBL] [Abstract][Full Text] [Related]
3. Comparison of assay formats for drug-tolerant immunogenicity testing.
Butterfield AM; Chain JS; Ackermann BL; Konrad RJ
Bioanalysis; 2010 Dec; 2(12):1961-9. PubMed ID: 21110740
[TBL] [Abstract][Full Text] [Related]
4. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
Song S; Yang L; Trepicchio WL; Wyant T
J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
[TBL] [Abstract][Full Text] [Related]
5. Non-normal random effects models for immunogenicity assay cut point determination.
Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of therapeutics: a matter of efficacy and safety.
Nechansky A; Kircheis R
Expert Opin Drug Discov; 2010 Nov; 5(11):1067-79. PubMed ID: 22827745
[TBL] [Abstract][Full Text] [Related]
7. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs.
Shankar G; Pendley C; Stein KE
Nat Biotechnol; 2007 May; 25(5):555-61. PubMed ID: 17483842
[TBL] [Abstract][Full Text] [Related]
8. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.
Krishna M; Nadler SG
Front Immunol; 2016; 7():21. PubMed ID: 26870037
[TBL] [Abstract][Full Text] [Related]
10. The challenges of immunogenicity in developing biosimilar products.
Wadhwa M; Thorpe R
IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.
Xue L; Clements-Egan A; Amaravadi L; Birchler M; Gorovits B; Liang M; Myler H; Purushothama S; Manning MS; Sung C
AAPS J; 2017 Nov; 19(6):1576-1586. PubMed ID: 29110222
[TBL] [Abstract][Full Text] [Related]
12. A semiparametric test to detect associations between quantitative traits and candidate genes in structured populations.
Li M; Reilly C; Hanson T
Bioinformatics; 2008 Oct; 24(20):2356-62. PubMed ID: 18753154
[TBL] [Abstract][Full Text] [Related]
13. A model-based statistic for detecting molecular markers associated with complex survival patterns in early-stage cancer.
Broët P; Moreau T
J Clin Bioinforma; 2012 Aug; 2(1):14. PubMed ID: 22866759
[TBL] [Abstract][Full Text] [Related]
14. Methods for testing equality of means of health care costs in a paired design study.
Zhou XH; Li C; Gao S; Tierney WM
Stat Med; 2001 Jun; 20(11):1703-20. PubMed ID: 11391697
[TBL] [Abstract][Full Text] [Related]
15. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
Kloks C; Berger C; Cortez P; Dean Y; Heinrich J; Bjerring Jensen L; Koppenburg V; Kostense S; Kramer D; Spindeldreher S; Kirby H
J Immunol Methods; 2015 Feb; 417():1-9. PubMed ID: 25602137
[TBL] [Abstract][Full Text] [Related]
16. A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?
Jaki T; Allacher P; Horling F
J Pharm Biomed Anal; 2016 Sep; 128():166-173. PubMed ID: 27262992
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists.
Xue L; Fiscella M; Rajadhyaksha M; Goyal J; Holland C; Gorovits B; Morimoto A
AAPS J; 2013 Jul; 15(3):852-5. PubMed ID: 23620231
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity.
Bivi N; Swearingen CA; Shockley TE; Sloan JH; Pottanat TG; Carter QL; Hodsdon ME; Siegel RW; Konrad RJ
J Immunol Methods; 2020 Nov; 486():112856. PubMed ID: 32916164
[TBL] [Abstract][Full Text] [Related]
20. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics.
Kropshofer H; Singer T
J Immunotoxicol; 2006 Sep; 3(3):131-6. PubMed ID: 18958693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
